Cosmo Pharmaceuticals (COPNZ) Stock Overview
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
COPNZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 97.25 |
| 52 Week High | CHF 107.80 |
| 52 Week Low | CHF 41.45 |
| Beta | 1.28 |
| 1 Month Change | 49.50% |
| 3 Month Change | 45.69% |
| 1 Year Change | 60.74% |
| 3 Year Change | 55.85% |
| 5 Year Change | 16.19% |
| Change since IPO | -37.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| COPNZ | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -6.7% | -0.6% | -0.007% |
| 1Y | 60.7% | 24.2% | 15.7% |
Return vs Industry: COPNZ exceeded the UK Pharmaceuticals industry which returned 24.2% over the past year.
Return vs Market: COPNZ exceeded the UK Market which returned 15.7% over the past year.
Price Volatility
| COPNZ volatility | |
|---|---|
| COPNZ Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: COPNZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: COPNZ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 332 | Giovanni Di Napoli | www.cosmopharma.com |
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
| COPNZ fundamental statistics | |
|---|---|
| Market cap | CHF 1.55b |
| Earnings (TTM) | CHF 56.17m |
| Revenue (TTM) | CHF 170.65m |
Is COPNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COPNZ income statement (TTM) | |
|---|---|
| Revenue | €182.27m |
| Cost of Revenue | €47.78m |
| Gross Profit | €134.49m |
| Other Expenses | €74.50m |
| Earnings | €59.99m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.76 |
| Gross Margin | 73.79% |
| Net Profit Margin | 32.91% |
| Debt/Equity Ratio | 0.09% |
How did COPNZ perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 23:10 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo Pharmaceuticals N.V. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |
| Julie Simmonds | Canaccord Genuity |